We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. OK, I agree | Cookies Policy

You are here

Magazine

8

New scientific communication on UTIPRO® PLUS

Following the publication of the experimental study by Fraile B et al. “Xyloglucan, hibiscus and propolis for the prevention of urinary tract infections: results of in vitro studies.” on Future Microbiology 2017; 12: 721-73, the authors presented a new communication at the VII International Congress of Histology and Tissue Engineering. Santiago de Compostela 5-8 Sept 2017. The results confirm the non-pharmacological barrier effect of xyloglucan and its utility in the prevention of urinary tract infections.

Read more

New scientific publication on RHINOSECTAN®

A new publication carried out in a nasal mucosa model demonstrates the barrier effect of Rhinosectan®, which confirms its utility in nasal respiratory diseases such as allergic rhinitis. Rhinosectan® is a Class I medical device and complies with the Essential Requirements of Directive 93/42/EEC and subsequent amendments. (CE, Noventure SL) De Servi B et al. Protective barrier properties of Rhinosectan® spray (containing xyloglucan) on an organotypic 3D airway tissue model (MucilAir): results of an in vitro study. Allergy Asthma Clin Immunol. 2017 Aug 10;13:37

Read more

Let's meet in..

2020, Nov 18

EWMA 2020

Read more